Charlottesville-based biopharmaceutical company Adial Pharmaceuticals, Inc. is making strides in the clinical-stage development of therapeutics for addiction and related disorders. The company's flagship product, AD04, a selective serotonin-3 antagonist, is currently undergoing Phase III clinical trial for the treatment of alcohol use disorder. In addition to its work on addiction, Adial Pharmaceuticals is also developing drug candidates for non-opioid pain reduction and other diseases and disorders. Founded in 2010, Adial Pharmaceuticals is committed to creating innovative solutions to some of the most pressing health issues of our time.